SOHO 2024 | Using MRD to identify which patients with AML will benefit the most from transplantation
Mark Levis
• 4 Sep 2024
Mark Levis, MD, PhD, John Hopkins University, Baltimore, MD, discusses using measurable residual disease (MRD) as a technique to identify patients with acute myeloid leukemia (AML) who are most likely to benefit from transplantation. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
